Australasian T1D Immunotherapy Collaborative
@ATIC_t1d
Followers
103
Following
95
Media
55
Statuses
133
A network of leading physicians, researchers and community members working together to 'Accelerate immunotherapy treatment for people with type 1 diabetes'
Australia and New Zealand
Joined July 2022
Interested in reading the publication? Read “Feasibility and validity of in-home self-collected capillary blood spot screening for type 1 diabetes risk” here: https://t.co/7DxxVR6i9P (3/3)
0
0
0
Not only does this make testing easier and more convenient than ever before, it means equitable access to screening for Aussies living in regional and remote areas. (2/3)
0
0
0
Front page news: ATIC clinical trials lead John Wentworth and colleagues have published the findings of the first at-home blood spot test for #type1diabetes in Australia! (1/3)
Exclusive: Melbourne scientists were confident a simple at-home blood test could accurately detect type 1 diabetes. They were right. @TheRMH @WEHI_research
@theheraldsun
#diabetes
https://t.co/51Elx0dGkE
2
1
1
🚨RESEARCH BREAKTHROUGH🚨 A @JDRF-funded, world-first clinical trial in Australia, has shown that a commonly prescribed drug (#baricitinib) can suppress the progression of #Type1Diabetes in those newly diagnosed with #T1D! 🔗 https://t.co/PDHoxelytY
@JDRFaus #GBDoc #Research
2
32
66
This line in the accompanying editorial sums up why: "The incidence of type 1 diabetes has tripled, its cause remains unknown, its prevention is still not possible, and its cure—nil." https://t.co/obhPLefWvm
nejm.org
Huge improvements in the treatment of many serious diseases have been made in the past half century, during which I have had the privilege of working first as a pediatric oncologist and later as a ...
4
10
51
Some important progress in autoimmune type 1 diabetes with a potent anti-inflammatory agent—baricitinib—preserving pancreas β-islet cell function in a small, randomized, placebo-controlled trial https://t.co/54TOb9dG09
@NEJM
2
46
182
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes | NEJM https://t.co/I73Lkf2IJx Great to see this just published showing a new potential benefit of jak inhibitors @GavegnanoGroup @WesElyMD @drugbuster21 @Boghuma @DrAndreKalil
nejm.org
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell f...
0
3
15
Jak inhibitors demonstrate efficacy in new onset T1D. https://t.co/lJqa5Qr6Lf
nejm.org
Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell f...
0
6
18
Big T1D research news out of Australia! Immune therapy baricitinib preserves beta cell function in newly diagnosed T1Ds.
0
1
6
A new trial in @NEJM from Thomas Kay, MBBS, PhD, of @SVIResearch, and colleagues suggests use of baricitinib (Olumiant; @EliLillyandCo) was associated with the preservation of beta-cell function among people with new-onset #Type1Diabetes. https://t.co/1ufqEWCZ2O
#T1D
0
4
4
Exciting results! Let the floodgates open for #type1diabetes disease modifying therapeutics! Kudos to the BANDIT team and its amazing leadership @TomKaySVI @SVIResearch @JDRF
In the BANDIT phase 2 trial, patients with recent-onset type 1 diabetes treated with the JAK inhibitor baricitinib had higher C-peptide levels at 48 weeks than those treated with placebo, suggesting preservation of β-cell function. Full trial results:
0
1
9
Exciting type 1 diabetes (T1D) research news! A JDRF-funded clinical trial, published in the renowned New England Journal of Medicine, demonstrated that baricitinib-a JAK inhibitor, which is critical to signaling pathways within both immune cells and beta cells (1/2)
3
22
76
A new study has found a drug used to treat immune diseases like rheumatoid arthritis could help preserve insulin function and suppress the progression of Type 1 diabetes. The findings of the BANDIT trial were published in the @NEJM today. https://t.co/YN4eHDueDU
thermh.org.au
A drug used to treat immune diseases like rheumatoid arthritis could help preserve insulin function and suppress the progression of Type 1 diabetes, a new study shows.
0
2
9
The BANDIT trial was supported by @JDRF and @JDRFaus and conducted by investigators at @StVincentsMelb @TheRMH, @RCHMelbourne and WCH Adelaide.
0
0
0
Here’s how the world-first Aussie research into the effect of #baricitinib in #t1d came about. Spoken by ATIC Chair Professor Thomas Kay. https://t.co/H2bQ5k1DXQ
1
3
8
Type 1 diabetes game changer - ATIC researchers led by Professor’s Thomas Kay and Helen Thomas have shown that a daily tablet of baricitinib can preserve beta cell function in people with newly diagnosed #T1D.
In the BANDIT phase 2 trial, patients with recent-onset type 1 diabetes treated with the JAK inhibitor baricitinib had higher C-peptide levels at 48 weeks than those treated with placebo, suggesting preservation of β-cell function. Full trial results:
0
3
14
Congratulations ATIC clinical trials lead, Associate Professor John Wentworth and the @Type1Screen team from @TheRMH and @WEHI_research for their commitment to equity in screening for #t1d. The at-home blood test was FINALIST in the @VicGovDH Victorian DoH Awards!
0
3
8
Join us for the November Beyond Insulin seminar, next Thursday November 23 at 1pm - 2pm AEST Speaker: Prof Natasha Rogers Title: CD47 – more than just a receptor on islets No registration necessary, all welcome! More info here: https://t.co/YsEzMXToC6
atic.svi.edu.au
Seminar 12 in the Beyond Insulin Seminar Series will be a summary of the findings from a recent discovery in CD47 receptors and type 1 diabetes by Professor Natasha Rogers (Westmead Hospital).
0
2
3
Do you have #diabetes? Do you know someone with diabetes? Register now to secure your FREE place at this important event at @FedSquare in Melbourne on Tuesday 14 Nov at 6pm #EndDiabetesStigma
This #WorldDiabetesDay, hear from those w lived experience, leaders, & experts on the effect of diabetes stigma & discrimination + their vision for what the world will look like when we #EndDiabetesStigma 📣Hosted by @NormanSwan & @RenzaS ➡️ https://t.co/XpBcew0rys
#WDD #WDD2023
1
7
13
Find out how you can take action to support the ‘Diabetes research changes lives’ campaign here: https://t.co/5iSkBa4v8n
diabetesaustralia.com.au
This World Diabetes Day, we’re talking about living well with diabetes. People living with diabetes should be able to access the information and ...
0
1
1